GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (FRA:DTC) » Definitions » Enterprise Value

Defence Therapeutics (FRA:DTC) Enterprise Value : €17.74 Mil (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Defence Therapeutics's Enterprise Value is €17.74 Mil. Defence Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was €-7.63 Mil. Therefore, Defence Therapeutics's EV-to-EBIT ratio for today is -2.33.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Defence Therapeutics's Enterprise Value is €17.74 Mil. Defence Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was €-7.56 Mil. Therefore, Defence Therapeutics's EV-to-EBITDA ratio for today is -2.35.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Defence Therapeutics's Enterprise Value is €17.74 Mil. Defence Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil. Therefore, Defence Therapeutics's EV-to-Revenue ratio for today is .


Defence Therapeutics Enterprise Value Historical Data

The historical data trend for Defence Therapeutics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Enterprise Value Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24
Enterprise Value
- 157.26 54.39 86.83 24.46

Defence Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.42 70.17 51.63 24.46 16.85

Competitive Comparison of Defence Therapeutics's Enterprise Value

For the Biotechnology subindustry, Defence Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Defence Therapeutics's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Defence Therapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Defence Therapeutics's Enterprise Value falls into.



Defence Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Defence Therapeutics's Enterprise Value for the fiscal year that ended in Jun. 2024 is calculated as

Defence Therapeutics's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Defence Therapeutics  (FRA:DTC) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Defence Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=17.743/-7.63
=-2.33

Defence Therapeutics's current Enterprise Value is €17.74 Mil.
Defence Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.63 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Defence Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=17.743/-7.564
=-2.35

Defence Therapeutics's current Enterprise Value is €17.74 Mil.
Defence Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.56 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Defence Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=17.743/0
=

Defence Therapeutics's current Enterprise Value is €17.74 Mil.
Defence Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Defence Therapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Defence Therapeutics Business Description

Traded in Other Exchanges
Address
200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.